MAM
BBIO icon

Myriad Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Myriad Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-37,200
Closed -$1.08M – 55
2020
Q1 		$1.08M Buy
+37,200
New +$1.15M 0.16% 68

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Myriad Asset Management's BBIO Position: Q2 2020 in Review

Myriad Asset Management sold out of BridgeBio Pharma (BBIO) in Q2 2020, closing a stake of 37,200 shares — an estimated $1.08M sold.

Myriad Asset Management first reported a position in BBIO in Q1 2020 and held it in 1 quarter. The position peaked at $1.08M in Q1 2020. 116 funds tracked by Wall St. Rank hold BBIO as of Q2 2020.

  • Myriad Asset Management reported no remaining BridgeBio Pharma position as of Q2 2020 after selling out during the quarter.
  • Myriad Asset Management sold 37,200 BridgeBio Pharma shares in Q2 2020, an estimated $1.08M.
  • Myriad Asset Management first reported a position in BridgeBio Pharma in Q1 2020 and held it in 1 quarter.
  • Myriad Asset Management's BridgeBio Pharma position peaked at $1.08M in Q1 2020.
  • 116 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2020.

Based on Myriad Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.